Vol.

No.

March 18, 2022Mar 18, 2022

DOWNLOAD THE PDF

Cover Story

DOJ takes over whistleblower suit claiming Memphis Methodist health system and West clinic ran afoul of false claims and anti-kickback laws

Under ordinary circumstances, business arrangements built around the 340B drug discount program remain shrouded in secrecy.

Conversation with The Cancer Letter Free

Ukraine NCI’s Nataliia Verovkina: “I returned to Kyiv. I’m doing my job. We will stand, and we will win.”

By Matthew Bin Han Ong

Free Obituary

Donald Pinkel, St. Jude founding medical director who brought the word “cure” to cancer, dies at 95

By Tim Wendel

Free Obituary

Reflecting on Donald Pinkel’s legacy as a physician, scientist, and humanitarian

By Mary Pinkel

Cancer History Project Free

Tim Wendel on the “Cancer Cowboys” and getting to know the ALGB

By Alexandria Carolan

Free In the Archives

The Donald Pinkel Archive: Remembering a “Cancer Cowboy,” civil rights advocate, and groundbreaking pediatric oncologist

In Brief

Andrew Chapman named director of Sidney Kimmel Cancer Center - Jefferson Health

“Call-on Congress” convenes advocates, legislators, health officials to rally for better CRC screening rates and outcomes

Camille Ragin named associate director of DEI at Fox Chase

Ashish Jha named White House coronavirus response coordinator

Martin Tallman named director of faculty mentorship and career development at Lurie Cancer Center

Dorothy Graves named assistant vice president and associate director for administration at Sylvester

Davey Daniel named chief medical officer of OneOncology

Clinical Roundup

ECOG-ACRIN opens NCI-MATCH treatment arm for dMMR and LAG-3-positive cancers as it continues to locate patients with BRAF mutations

University of Pittsburgh study finds malaria drug could combat chemotherapy-resistant head and neck cancers

OSUCCC – James study highlights impact of intersecting identities in cancer risk

Yale study identifies class of oncogenic fusions in lung and pancreatic cancer

Yale scientists discover pathogenic mechanism in hematological malignancies

Researchers measure drop in cancer detection in Ontario due to COVID-19

Drugs & Targets

FDA approves FoundationOne CDx as companion diagnostic for EGFR therapeutics targeting exon 19 deletions or exon 21 substitutions in NSCLC

Strata Oncology Sentinel Trial for personalized cancer recurrence monitoring enrolls first patient

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues